Abstract
Heat shock proteins are members of a large family that function normally in nascent protein folding and the removal of damaged proteins and are able to respond to cellular stresses such as thermal insult to prevent catastrophic protein aggregation. A number of the most common neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases are characterized by such abnormal protein folding and aggregation, and the induction of the heat shock response is observed in these cases through their increased expression and often localization within the inclusions. Tau proteins form the major structural component of the neurofibrillary protein aggregates that correlate with cognitive decline in Alzheimer’s disease, and appropriately this abnormal tau is targeted for corrective action by the heat shock proteins that recognize sequence motifs that are normally masked though microtubule binding. This specific heat shock response to the formation of abnormal tau can also be targeted pharmacologically to inhibit the refolding pathways and drive the degradation of tau species that are thought to be pathogenic. This review discusses the recent advances of the roles of heat shock proteins in this process.
Keywords: Heat shock proteins, neurodegeneration, aggregation, chaperones, proteasome, ubiquitin, autophagy, tau protein.
Current Alzheimer Research
Title:Targeting Heat Shock Proteins in Tauopathies
Volume: 7 Issue: 8
Author(s): M. DeTure, C. Hicks and L. Petrucelli
Affiliation:
Keywords: Heat shock proteins, neurodegeneration, aggregation, chaperones, proteasome, ubiquitin, autophagy, tau protein.
Abstract: Heat shock proteins are members of a large family that function normally in nascent protein folding and the removal of damaged proteins and are able to respond to cellular stresses such as thermal insult to prevent catastrophic protein aggregation. A number of the most common neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases are characterized by such abnormal protein folding and aggregation, and the induction of the heat shock response is observed in these cases through their increased expression and often localization within the inclusions. Tau proteins form the major structural component of the neurofibrillary protein aggregates that correlate with cognitive decline in Alzheimer’s disease, and appropriately this abnormal tau is targeted for corrective action by the heat shock proteins that recognize sequence motifs that are normally masked though microtubule binding. This specific heat shock response to the formation of abnormal tau can also be targeted pharmacologically to inhibit the refolding pathways and drive the degradation of tau species that are thought to be pathogenic. This review discusses the recent advances of the roles of heat shock proteins in this process.
Export Options
About this article
Cite this article as:
DeTure M., Hicks C. and Petrucelli L., Targeting Heat Shock Proteins in Tauopathies, Current Alzheimer Research 2010; 7 (8) . https://dx.doi.org/10.2174/156720510793611565
DOI https://dx.doi.org/10.2174/156720510793611565 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Recent Advances of Biology and Medicinal Chemistry of Prion Protein and Prions: On the Road to Therapeutics)
Current Topics in Medicinal Chemistry Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Editorial [Hot Topic:Neurodegenerative Disorders: From Molecules to Man (Part 1) (Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito)]
CNS & Neurological Disorders - Drug Targets Stem Cell Lineage Commitment by Electrical Fields and the Potential Application in Drug Discovery
Current Drug Metabolism The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Therapeutic and Mechanistic Effects of Curcumin in Huntington’s Disease
Current Neuropharmacology Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies
Current Alzheimer Research Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
Current Genomics Putative Molecular Interactions Involving Naturally Occurring Steroidal Alkaloids from Sarcococca hookeriana Against Acetyl- and Butyryl- Cholinesterase
Current Bioinformatics Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study
Central Nervous System Agents in Medicinal Chemistry